Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

03 sept. 2020 16h05 HE | Source: Relay Therapeutics, Inc.

Relay Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Trial of RLY-4008, a Highly Selective FGFR2 Inhibitor

CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging...
27 août 2020 06h50 HE | Source: Relay Therapeutics, Inc.

Relay Therapeutics Reports Second Quarter 2020 Financial Results

CAMBRIDGE, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging...
20 juil. 2020 16h05 HE | Source: Relay Therapeutics, Inc.

Relay Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging...
15 juil. 2020 20h50 HE | Source: Relay Therapeutics, Inc.

Relay Therapeutics Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass., July 15, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging...